CLIMB BIO, INC. (CLYM) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 41.90M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 8.11M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -64.76M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $41.90M | (m) | $8.11M | $-64.76M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $38.76M | (m) | $7.64M | $-60.08M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $46.71M | (m) | $8.05M | $-67.88M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $38.77M | (m) | $8.67M | $-59.50M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $35.94M | (m) | $7.62M | $-56.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $30.41M | (m) | $7.11M | $-102.03M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $14.18M | (m) | $5.56M | $-82.02M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $11.35M | (m) | $5.10M | $-76.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $8.14M | (m) | $2.83M | $-69.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $10.78M | (m) | $3.10M | $-19.84M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $15.41M | (m) | $12.81M | $-40.27M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $17.21M | (m) | $13.50M | $-44.71M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $18.59M | (m) | $14.63M | $-48.45M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $23.67M | (m) | $15.62M | $-55.44M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $26.21M | (m) | $6.99M | $-45.13M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $26.89M | (m) | $6.25M | $-46.28M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $29.15M | (m) | $5.70M | $-46.92M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $25.88M | (m) | $4.98M | $-41.92M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $22.05M | (m) | $3.74M | $-35.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.77M | (m) | $707.00K | $-20.93M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |